In all, 18 patients (30-56 years; median 49) with MDS underwent allogeneic HSCT from related (n ¼ 12) or unrelated (n ¼ 6) donors after a conditioning regimen comprising thiotepa, cyclophosphamide, and TBI. GVHD prophylaxis consisted of cyclosporine (n ¼ 15) or tacrolimus (n ¼ 3) with short-course methotrexate. Four patients had low-risk disease (refractory anemia or complete remission after chemotherapy) and 14 patients had highrisk disease (RAEB, RAEB-t, or AML). Grade II-IV acute GVHD developed in six patients and chronic GVHD in 10. With a median follow-up of 31 months, the 2-year survival probability is 75% for low-risk patients and 57% for high-risk patients. One patient died of leukemia and six of treatment-related causes. This conditioning regimen requires further study in patients with MDS.
geneic hematopoietic stem cell transplantation Allogeneic HSCT is the only curative therapy available for MDS. The main obstacles to success of HSCT are relapseand treatment-related mortality (TRM).
1 Risk of recurrence is influenced by the number of blasts in the marrow and the presence of cytogenetic abnormalities before HSCT. [1] [2] [3] No conditioning regimen has been shown to be significantly superior to the standard cyclophosphamide (CY)-TBI or busulfan (BU)-CY combinations.
1,4 Thiotepa (TT) is a cell-cycle-independent alkylating agent with limited extramedullary toxicity. 5 We have evaluated TT-CY-TBI as a conditioning regimen for MDS patients to see if relapse can be redcued without an increase in TRM.
Patients and methods
In total, 18 patients with primary MDS received allogeneic HSCT between June 1994 and November 2001. Characteristics of the patients are listed in Table 1 . Seven patients had received chemotherapy for MDS. Complete remission (CR), defined as a marrow blast count of o5% and normal peripheral blood counts, was achieved in one patient, and a second RA phase (marrow blast count of o5% but subnormal blood counts) in another.
Patients with RA, CR, or second RA were considered low-risk, and the others (RAEB, RAEB-t, or AML) were considered high-risk.
The conditioning regimen consisted of intravenous TT 200 mg/m 2 /day for 2 consecutive days (total 400 mg/m 2 ); intravenous CY, 2250 mg/m 2 /day for 2 consecutive days (total 4500 mg/m 2 ); and TBI (12.5 Gy in five fractions or 12 Gy in four fractions). For patients aged 440 years, the CY dose was reduced to 2000 mg/m 2 /day for 2 consecutive days. For six of nine patients aged 450 years, the CY dose was reduced to 1800 mg/m 2 /day for 2 consecutive days, and the TBI dose was reduced to 10 Gy in four fractions.
Regimen-related toxicities were graded in a standard fashion. 6 In total, 11 patients received marrow (n ¼ 8) or blood stem cells (n ¼ 3) from HLA-identical siblings, one received marrow from an HLA-identical nonsibling related donor. Five patients marrow from serologically HLA-identical unrelated donors; three mismatched at the allele level. One patient received HLA-mismatched cord blood.
Bone marrow was harvested by standard technique using general anesthesia with a target yield of X2 Â 10 8 nucleated cells/kg recipient weight. Blood stem cell donors were mobilized with G-CSF, and the target cell yield was X2 Â 10 6 CD34 þ cells/kg recipient weight. GVHD prophylaxis consisted of MTX and cyclosporine A (CSP) in 15 patients, and MTX and tacrolimus in three.
MTX was given intravenously to seven patients at a dose of 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6. From February 2000, the MTX dose was reduced to 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3 and 6 for nine patients. The starting dose of CSP (3 mg/kg/day) or tacrolimus (0.03 mg/kg/day) was administered by continuous intravenous infusion from day À1. These doses were modified to maintain a whole blood level of 270-300 ng/ ml of CSP or 15-20 ng/ml of tacrolimus. CSP or tacrolimus was tapered off from day 50 in patients without evidence of GVHD and discontinued on day 150. If grade II-IV acute GVHD developed, patients were treated with prednisolone in doses ranging between 1 and 2 mg/kg/ day. Patients with extensive chronic GVHD were treated with prednisolone and CSP or tacrolimus. Both acute and chronic GVHD were graded according to previously published criteria. 7, 8 All patients were isolated in a laminar air-flow room and were given antibiotics and antifungal agents for gastrointestinal decontamination until engraftment. Lenograstim (5 mg/kg/day) was given by intravenous infusion over 24 h starting on day 1, and continued until engraftment. DNA microsatellite studies were performed in one patient who developed acute GVHD but experienced primary graft failure thereafter. All patients received 5 g IVIG once a week from day À6 to day 98. Regimen-related toxicities are shown in Table 2 . Stomatitis and diarrhea occurred in more than half of the patients. VOD was not seen. Table 3 shows patient outcomes. Acute grade II-IV GVHD developed in six patients, including grade III in one and grade IV GVHD in two. Patient 1 developed a skin rash on day 5, which was diagnosed as GVHD on biopsy. Although she experienced primary graft failure thereafter, her bone marrow sample on day 35 showed complete donor type of microsatellites. Extensive chronic GVHD occurred in six patients, and limited chronic GVHD in four patients.
The median follow-up for the 11 patients alive in CR was 31 months (range, 23-90 months). Current Karnofsky scores were 90-100% in 10 survivors and 80% in one. The estimated 2-year probability of survival was 61% for all patients (Figure 1) . The estimated probability of 2-year survival was 75% in the low-risk group and 57% in the Regimen-related toxicities were graded using the system described by Bearman et al. 6 CNS ¼ central nervous system; GI ¼ gasrointestinal.
high-risk group (Figure 2) . The estimated probability of 2-year survival was 75% in the patients transplanted from a matched family donor and 33% in patients transplanted from an unrelated donor. Patient 18 did not attain CR after HSCT, and died of leukemia on day 75. Two patients died infection on day 19 and 178, two of idiopathic interstitial pneumonia on day 226 and 255, one of liver failure from grade IV GVHD on day 138, and one of brain infarction owing to thrombotic microangiopathy on day 66. The cumulative incidence of TRM was 33% at 1 year.
Discussion
The intensity of the conditioning regimen and graft-versustumor effects are probably equally important in MDS. [9] [10] [11] [12] A variety of conditioning regimens have been used in transplantation for MDS.
1, 4 Two studies showed that regimens containing BU-CY with an additional agent yielded better disease-free survival than BU-CY or CY-TBI. 13, 14 In another study, a regimen consisting of BU-CY-TBI resulted in a relatively low relapse rate but high TRM. 15 TT is characterized by an initial, rapid diffusionmediated uptake into tumor cells followed by irreversible binding to intracellular macromolecules. [16] [17] [18] The major dose-limiting toxicities of TT affect the central nervous system and the gastrointestinal tract. 19 TT has been added safely to CY-TBI in patients with AML or ALL.
5,20 Dose modification of both TBI and CY in our study for older patients may have contributed to a relatively low incidence of regimen-related toxicity.
Although the numbers are small, the lack of relapse is encouraging. The drawbacks of our study are a small number of patients enrolled over several years, and heterogeneity of therapy. Based upon our data, further study of this regimen is warranted to confirm its efficacy. or in CR or second RA obtained after chemotherapy were defined as belonging to the low-risk group and patients with RAEB, RAEB-t, or AML were defined as belonging to the high-risk group.
